drugset / Trial / NCT00004062
Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
Phase 1
Completed
Lucille P. Markey Cancer Center at University of Kentucky
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
Timeline
- Start
- 1999-07
- Primary completion
- —
- Completion
- 2006-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Subcutaneous |
| Background | Liothyronine | Small molecule | — | Oral |